Multiple antidepressant potential modes of action of curcumin: A review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and neuroprotective effects by Lopresti, A.L. et al.
MURDOCH RESEARCH REPOSITORY
http://researchrepository.murdoch.edu.au
This is the author's final version of the work, as accepted for publication following peer review but without the
publisher's layout or pagination.
Lopresti, A.L. , Hood, S.D. and Drummond, P.D. (2012) Multiple antidepressant potential modes of action
of curcumin: a review of its anti-inflammatory, monoaminergic, antioxidant, immune-modulating and
neuroprotective effects. Journal of Psychopharmacology, 26 (12). pp. 1512-1524.
http://researchrepository.murdoch.edu.au/12507
Copyright © The authors
It is posted here for your personal use. No further distribution is permitted.
http://tweaket.com/CPGenerator/?id=12507
1 of 1 16/01/2013 9:38 AMAntidepressant Potential Modes of Action of Curcumin   
Multiple antidepressant potential modes of 
action of curcumin: A review of its anti-
inflammatory, antioxidant, immune-modulating 
and neuroprotective effects 
 
Adrian L Lopresti
1, Sean D Hood
2, Peter D Drummond
1 
1 School of Psychology, Murdoch University, Perth, Western Australia, 6150, Australia 
2 School of Psychiatry & Clinical Neurosciences, University of Western Australia, 
Perth, Western Australia, 6009, Australia
 
Correspondence: 
E: a.lopresti@murdoch.edu.au,  
P: +61 0892486904  
F: +61 0892484274  
A: 4/ 165 Summerlakes Pde Ballajura Western Australia 6066, Australia 
Keywords: curcumin, depression, natural antidepressant, herbal treatment, turmeric, 
inflammation 
  Word Count: 161 (Abstract), 6679 (Text). 4 x Figures Antidepressant Potential Modes of Action of Curcumin   
Abstract 
Curcumin is the principal curcuminoid of the popular Indian spice turmeric and has 
attracted increasing attention for the treatment of a range of conditions. Research into its 
potential as a treatment for depression is still in its infancy, although several potential 
antidepressant mechanisms of action have been identified. Research completed to date 
on the multiple effects of curcumin is reviewed in this paper, with a specific emphasis 
on the biological systems that are compromised in depression. The antidepressant 
effects of curcumin in animal models of depression are summarised, and its influence 
on neurotransmitters such as serotonin and dopamine is detailed. The effects of 
curcumin in moderating hypothalamus-pituitary-adrenal (HPA) disturbances, lowering 
inflammation, and protecting against oxidative stress, mitochondrial damage, 
neuroprogression and intestinal hyperpermeability, all of which are compromised in 
major depressive disorder, are also summarised. With increasing interest in natural 
treatments for depression, and efforts to enhance current treatment outcomes, curcumin 
is presented as a promising novel, adjunctive or stand-alone natural antidepressant. 
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Major depression is one of the most common psychiatric disorders in the Western 
World and is the leading cause of disability (as measured by years lived with a 
disability). In the year 2000 it was the 4th leading contributor to the global burden of 
disease and by the year 2020 is projected to be second only to ischemic heart disease in 
the amount of disability experienced by sufferers (WHO, 2008).   
Major depression is a heterogeneous disorder recognised as having a complex and 
multifactorial aetiology originating from the interaction between environmental and 
genetic factors. As depicted in figure 1, these lead to a range of disturbances including: 
neurotransmitter imbalances associated with lowered serotonin, dopamine and 
noradrenaline, and increased glutamate activity; HPA disturbances typically 
characterised by increased HPA activity and glucocorticoid resistance; dysregulated 
inflammatory pathways as evidenced by increased levels of proinflammatory cytokines, 
acute phase proteins and kynurenine pathway metabolites; increased oxidative and 
nitrosative damage associated with reduced antioxidant defences; neuroprogression 
resulting in neurodegeneration, apoptosis, reduced neurogenesis and neuronal plasticity; 
and mitochondrial disturbances in the form of increased damage to mitochondria and 
mitochondrial DNA, and lowered ATP production. (Leonard and Maes, 2012; Maes et 
al., 2009c; Manji et al., 2001; Raison and Miller, 2011). It is these multiple pathways 
that make the effective treatment of depression difficult, with current therapies 
achieving far from optimal remission rates of between 20 to 40 percent (Warden et al., 
2007). This has motivated a search for alternative pharmacological, psychological, 
environmental, and even nutraceutical treatment options to enhance current treatment 
outcomes. 
<<<insert Figure 1 near here> Antidepressant Potential Modes of Action of Curcumin   
Given the multifactorial nature of depression, an enhancement of treatment efficacy is 
likely to occur from therapies that target multiple mechanisms. This is likely to be 
achieved by combining therapies and/or utilising treatments with multiple mechanisms 
of action. Curcumin, derived from the spice turmeric, is a potential natural substance 
that may at least partly fulfil this criterion.  As demonstrated in figure 2, curcumin has 
been shown to have a large array of molecular targets of action which may prove to be 
beneficial for the treatment and prevention of depression and other diseases (Aggarwal 
and Sung, 2009; Gupta et al., 2012). This has already led to two published brief reviews 
highlighting the potential antidepressant effects of curcumin (Kulkarni et al., 2009; 
Kulkarni and Dhir, 2010).<<<insert Figure 2 near here> 
Interest in the benefits of curcumin has increased dramatically over the past decade with 
a number of clinical studies currently underway investigating its efficacy for treating 
and preventing a range of diseases including certain cancers (e.g., 
http://clinicaltrials.gov/ct2/show/NCT00094445) , Alzheimer’s disease (e.g.,  
http://www.anzctr.org.au/trial_view.aspx?id=336793) and musculoskeletal conditions 
(e.g.,   http://clinicaltrials.gov/ct2/show/NCT00752154)In addition, at least one 
unpublished study has been completed investigating the antidepressant effects of 
curcumin (http://clinicaltrials.gov/ct2/show/NCT01022632), although the outcomes of 
this study have not yet been released. The research completed to date on the multiple 
effects of curcumin is reviewed in this paper, with a specific emphasis on the biological 
systems that are compromised in depression. The antidepressant effects of curcumin in 
animal models of depression is summarised, and its effect on neurotransmitters, HPA 
disturbances, inflammation, oxidative stress, mitochondria, neuroprogression and 
intestinal hyperpermeability, all of which are disturbed in depression, are detailed. Antidepressant Potential Modes of Action of Curcumin   
Animal behavioural models of depression 
Despite the fact that no animal model is able to incorporate all aspects of depressive 
symptoms in humans, the forced swimming test (FST) is a reliable and valid tool for 
screening the antidepressant effects of drugs (Petit-Demouliere et al., 2005). Animals 
(typically rats and mice) are subjected to two trials where they are forced to swim in an 
inescapable cylinder filled with water. The time animals spend immobile in the second 
trial provides a measure of despair, and has been shown to be reduced by antidepressant 
drugs (Petit-Demouliere et al., 2005).  
The tail suspension test (TST) is another animal model of depression that has good 
reliability and predictive validity (Cryan et al., 2005). In the TST, animals are subjected 
to the short-term, inescapable stress of being suspended by their tail, with time spent in 
an immobile posture providing a measure of depressive behaviour. Various 
antidepressant medications have been shown to reverse immobility and to promote 
escape-related behaviour (Steru et al., 1985).  
Antidepressant effects of curcumin in animal models 
The antidepressant effects of curcumin have been evaluated through the FST and TST 
in over a dozen studies in the past decade. These have consistently demonstrated that 
both acute (Arora et al., 2011; Chimakurthy and Talasila, 2010; Gilhotra and Dhingra, Antidepressant Potential Modes of Action of Curcumin   
2010; Kulkarni et al., 2008; Sanmukhani et al., 2011; Wang et al., 2008) and chronic 
(Bhutani et al., 2009; Huang et al., 2011; Li et al., 2009; Sanmukhani et al., 2011; Xia et 
al., 2007; Xu et al., 2005b) administration of curcumin to rats and mice reduces 
immobility time.  
For example, both in the acute models of FST and TST, and the chronic model of FST 
with a water wheel, curcumin had significant antidepressant-like activity compared with 
a vehicle control. The effects of curcumin were similar to that of fluoxetine and 
imipramine although when administered in combination, antidepressant effects were not 
enhanced (Sanmukhani et al., 2011). Similar results have been found in other animal 
models of depression, with curcumin having similar antidepressant efficacy to 
fluoxetine (Li et al., 2009; Wang et al., 2008). 
Bilateral olfactory bulbectomy in rats causes changes in behaviour, and in the 
endocrine, immune and neurotransmitter systems, that lead to many characteristics seen 
in patients with major depression. Bulbectomy is believed to cause major dysfunction in 
the cortical-hippocampal-amygdala circuit similar to that seen in people suffering from 
major depression (Song and Leonard, 2005). Chronic, but not acute administration of 
antidepressants corrects most of the changes evoked by bulbectomy (Song and Leonard, 
2005).  A study assessing the effects of curcumin demonstrated that its chronic Antidepressant Potential Modes of Action of Curcumin   
administration was also able to reduce immobility time and reverse the behavioural 
abnormalities induced by bulbectomy (Xu et al., 2005a). 
By depleting monoamines and increasing oxidative stress, reserpine is a drug that 
increases pain and depressive symptoms. An investigation into the protective effects of 
curcumin on the reserpine-induced pain-depression dyad in rats demonstrated that 
curcumin was effective in ameliorating a number of behavioural changes induced by 
reserpine (Arora et al., 2011). Finally, depressive-like behaviours characterised by a 
decrease in sugar consumption and an increase in immobility time were induced by 3 
weeks of corticosterone injections in rats. Concurrent treatment with curcumin reduced 
depressive-like behaviours, demonstrated by a 46% increase in sucrose consumption 
and a 57% reduction in immobility time compared with rats receiving corticosterone 
injections alone (Huang et al., 2011). 
Based on the studies reviewed, in animal models of depression, oral and intraperitoneal 
curcumin appear to have potent antidepressant properties with effects similar to 
antidepressants such as the serotonin reuptake inhibitor fluoxetine and the tricyclic 
imipramine. Antidepressant Potential Modes of Action of Curcumin   
Depression and immuno-inflammation 
Interest in the association between major depression and inflammation was triggered by 
studies demonstrating increased levels of inflammatory mediators in depression. This 
led to the development of inflammatory models of depression and prompted initial 
comparisons between the symptoms of depression and ‘sickness behaviours’ such as 
anorexia, soporific effects, reduction of locomotor activity and exploration, anhedonia 
and cognitive disturbances (Dantzer et al., 2011; Raison et al., 2006). These were later 
confirmed to be distinct conditions, with sickness behaviour an adaptive, acute state, 
whereas depression is a disabling, progressive disorder (Maes et al., 2012a)  
Three recent meta-analyses have all confirmed that depression is associated with 
elevated levels of pro-inflammatory cytokines and other inflammatory mediators. 
Howren et al. (2009) concluded that depression in clinic and community samples was 
associated with high levels of C-reactive protein (CRP), interleukin-1 (IL-1), and 
interleukin-6 (IL-6). In a meta-analysis by Dowlati et al. (2010), levels of tumour 
necrosis factor-α (TNF-α) and IL-6 were significantly higher in depressed patients than 
controls. Finally, a meta-analysis by Liu et al. (2012) demonstrated that the blood levels 
of soluble interleukin-2 receptors (sIL-2R), TNF-α and IL-6 were all significantly 
higher in patients with major depressive disorder than in controls. There is also 
evidence that major depression is characterised by a Th-1-like cell-mediated response, Antidepressant Potential Modes of Action of Curcumin   
as evidenced by increased production of interferon-γ (IFN-γ), increased IFN-γ/IL-4 
ratios and increased neopterin levels (Maes et al., 1994; Myint et al., 2005). 
Further support for the relationship between depression and inflammation is provided 
by a meta-analysis on the anti-inflammatory effects of antidepressant medications, 
which concluded that antidepressants reduced levels of cytokines IL-1β and possibly IL-
6, but not TNF-α (Hannestad et al., 2011). The N-methyl-D-aspartate (NMDA) receptor 
antagonist ketamine, which has rapid antidepressant effects in treatment-resistant 
patients with major depressive disorder, also has anti-inflammatory effects (Loix et al., 
2011; Mathew et al., 2012)  
While increased inflammation is not found in all patients with depression, it is argued 
that its effects may be relevant to a subset of patients (Raison and Miller, 2011). 
Researchers have also become increasingly interested in the impact of inflammation on 
kynurenine pathway metabolites which have both neurotoxic and neuroprotective 
qualities (Dantzer et al., 2011; Maes et al., 2011c).  
Immuno-inflammatory effects of curcumin 
Effects of curcumin on inflammatory pathways 
Extensive research using a wide range of in vitro models has indicated that curcumin 
can reduce the inflammatory response by regulating the production of a range of Antidepressant Potential Modes of Action of Curcumin   
inflammatory molecules (Basnet and Skalko-Basnet, 2011; Srivastava et al., 2011). 
Research performed in animals also provides strong evidence for the beneficial effects 
of curcumin in various diseases associated with inflammation including inflammatory 
bowel disease, obesity, cardiovascular disease and certain cancers (Gupta et al., 2012).  
Evidence of anti-inflammatory effects in human studies is accumulating and has so far 
been promising. For example, in a clinical trial on osteoarthritis patients, the 
administration of a patented form of curcumin (Meriva
®) significantly reduced a 
number of inflammatory markers including IL-1β, IL-6, and the erythrocyte 
sedimentation rate (ESR) (Belcaro et al., 2010). In another randomised clinical trial, 
curcumin (BCM-95
®) given to patients with rheumatoid arthritis significantly reduced 
the ESR to levels similar to that obtained from the non-steroidal anti-inflammatory 
drug, diclofenac sodium (Chandran and Goel, 2012). Further evidence of the anti-
inflammatory effects of curcumin was demonstrated in a randomised, double-blind, 
placebo-controlled study on patients with overt type 2 diabetic nephropathy where 
curcumin administration reduced serum levels of TGF-β and IL-8, and urinary IL-8 
(Khajehdehi et al., 2011). Finally, in another study on patients with type 2 diabetes, 
curcumin lowered levels of IL-6 and TNF-α significantly more than placebo (Usharani 
et al., 2008). Antidepressant Potential Modes of Action of Curcumin   
COX-2 selective inhibitors are a form of non-steroidal anti-inflammatory drug (NSAID) 
that directly targets COX-2, an enzyme responsible for the production of prostaglandin 
E2 (PGE2). PGE2 is a pro-inflammatory chemical messenger involved in pain, fever and 
swelling. In normal conditions, COX-2 is not expressed in most cells, but elevated 
levels are found during inflammation which, in turn, stimulates the production of PGE2. 
As a co-factor, COX-2 is associated with the increased expression of IDO (Basu et al., 
2006; Cesario et al., 2011; Lee et al., 2009) and with inflammatory cytokines (Abbasi et 
al., 2012).  
Studies in the area of depression have provided evidence of increased PGE2 production 
and COX-2 expression in depressed people. For example, increased concentrations of 
PGE2 in the saliva of patients with major depressive disorder were identified (Ohishi et 
al., 1988). Moreover, increased levels of PGE2 were reported both in the CSF and serum 
of depressed patients (Calabrese et al., 1986; Linnoila et al., 1983). Increased expression 
of the genes encoding for COX-2 were also found in the peripheral blood cells of 
patients with recurrent depression (Galecki et al., 2012). The antidepressants fluoxetine 
and amitriptyline also inhibit cytokine-induced PGE2 production by inflammatory cells 
(Yaron et al., 1999). Recent interest in the potential of COX-2 inhibitors to augment 
antidepressant therapies also show promise, with a number of positive findings from 
animal models of depression and from preliminary human clinical trials (Muller and 
Schwarz, 2008).  Antidepressant Potential Modes of Action of Curcumin   
In a six-week double-blind, placebo-controlled trial, depressed patients treated with a 
combination of fluoxetine and the COX-2 inhibitor, celecoxib, experienced greater 
improvement in mood compared with those treated with a combination of fluoxetine 
and placebo (Akhondzadeh et al., 2009). In a double-blind, add-on study using the 
noradrenergic reuptake inhibitor reboxetine as the antidepressant, Muller et al. (2006)  
obtained a similar outcome. The combination of reboxetine and celecoxib led to 
significantly greater improvements compared with the reboxetine-alone treated group. 
Also, in an open-label pilot study, the mixed COX-1/COX-2 inhibitor acetylsalicylic 
acid accelerated the antidepressant effect of fluoxetine and increased the response rate 
in depressed non-responders to fluoxetine (Mendlewicz et al., 2006). More recently, 
celecoxib enhanced the efficacy of the serotonergic antidepressant sertraline in 40 
depressed patients. Patients in the celecoxib and sertraline group experienced a 
significantly greater response (95%) and remission (35%) rate compared with those 
receiving placebo and sertraline (50% response and 5% remission) (Abbasi et al., 2012). 
Investigation into the biological activities of curcumin have demonstrated that it can 
down-regulate COX-2 expression and PGE2 synthesis (Hong et al., 2004; Lee et al., 
2011; Moriyuki et al., 2010; Plummer et al., 1999), therefore providing an alternative 
natural option as a COX-2 inhibitor. While further human clinical studies are required 
in this area, the promising antidepressant findings of pharmaceutical COX-2 inhibitors Antidepressant Potential Modes of Action of Curcumin   
provides another potential mechanism of action of for the antidepressant effect of 
curcumin. 
Effects of curcumin on immune pathways 
<<<insert Figure 3 near here> 
IDO is an enzyme expressed in multiple cell types including macrophages, dendritic 
cells, astrocytes and microglia and is strongly activated by the pro-inflammatory 
cytokine IFN-γ and to a lesser extent TNF-α, IL-1, and IL-6. IDO can also be induced 
by lipopolysaccharides (LPS) (Chen and Guillemin, 2009; Stone et al., 2012). As shown 
in Figure 3, IDO is important in depression as it reduces serotonin synthesis by 
catabolising tryptophan, the primary amino-acid precursor of serotonin, into kynurenine 
pathway metabolites.  The role of serotonin in depression is already well recognised; 
however, accumulating research shows that a number of kynurenine pathway 
metabolites can impact on several mechanisms associated with depression (Maes et al., 
2011c; Maes et al., 2007). For example, excess levels of the NMDA agonist and 
kynurenine pathway metabolite, quinolinic acid (QUIN), are excitotoxic, leading to 
degenerative changes in the central nervous system. It can increase the generation of 
free radicals and induce lipid peroxidation. The damaging effects of QUIN can also 
contribute to mitochondrial degeneration and in experimental models QUIN has 
anxiogenic effects (Stone et al., 2012). Excess QUIN levels were found in depression Antidepressant Potential Modes of Action of Curcumin   
(Raison et al., 2010; Steiner et al., 2011), and in neurological conditions such as 
Alzheimer’s disease, Parkinson’s disease and multiple sclerosis (Kincses et al., 2010; 
Zádori et al., 2009). 
Another kynurenine pathway metabolite and NMDA antagonist, kynurenic acid 
(KYNA), is considered neuroprotective and inversely regulates dopaminergic activity. 
Its balance with QUIN is important as it is considered protective against the 
excitotoxicity of QUIN (Myint, 2012). KYNA levels were found to be low in 
depression (Maes et al., 2011b; Myint et al., 2007) and, more recently, were observed to 
be particularly low in patients with somatization (Maes et al., 2011b; Maes and Rief, 
2012). KYNA levels were also associated with an increased risk of depression in people 
undergoing IFN-α treatment for hepatitis C virus (Wichers et al., 2005). 
Research into the effects of curcumin on IDO expression is only preliminary. However, 
studies identified to date have been positive. One study demonstrated that curcumin 
significantly inhibited the expression and activity of IDO in IFN-γ-stimulated bone 
marrow dendritic mice cells (Jeong et al., 2009). In a study on cancer cells induced by 
IFN-γ, curcumin was also reported to inhibit the expression of IDO (Zhang et al., 2008). 
Finally, in an in vitro and in vivo investigation, curcumin delivered to mice significantly 
attenuated LPS-induced increases in IDO expression in bone marrow-derived dendritic 
cells (Jung et al., 2010). Antidepressant Potential Modes of Action of Curcumin   
Further evidence of curcumin’s immuno-modulating effects are demonstrated by its 
ability to lower Th-17 autoimmune responses (Kanakasabai et al., 2012; Xie et al., 
2009) which have recently been shown to be upregulated in major depression (Chen et 
al., 2011). Curcumin also decreases the expression of Th-1 cytokines (e.g., IFN-γ, TNF-
α) and increases the expression of Th-2 cytokines (e.g., IL-4 and IL-10) (Bereswill et 
al., 2010; Zhang et al., 2006). This may prove to be beneficial for the treatment of 
depression given consistent findings of increased Th-1-like cell-mediated responses in 
major depression (Maes, 2011; Maes et al., 1994; Myint et al., 2005).  
Several studies have also investigated the influence of curcumin on the 
lipopolysaccharide (LPS)-induced immune response. One such study revealed that the 
systemic administration of LPS to rabbits increased core temperature and hypothalamic 
levels of glutamate and hydroxyl radicals along with increased plasma levels of TNF-α, 
IL-1β, and IL-6. Pre-treatment with curcumin one hour before an intravenous dose of 
LPS significantly reduced the LPS-induced overproduction of circulating TNF-α, IL-1β, 
and IL-6, and brain glutamate, PGE2, and hydroxyl radicals (Huang et al., 2008). 
Depression and neurotransmitters 
The monoamine-deficiency theory is the most recognised and investigated causative 
model of major depression. It is postulated as the primary mechanism of action of Antidepressant Potential Modes of Action of Curcumin   
popular pharmaceutical antidepressants, such as selective serotonin reuptake inhibitors 
(SSRIs) and serotonin-noradrenaline reuptake inhibitors (SNRIs), is to increase the 
availability of monoamines such as serotonin, noradrenaline (i.e., norepinephrine) and, 
possibly, dopamine. According to this theory, the underlying pathophysiological basis 
of depression is a depletion of these neurotransmitters in the central nervous system 
(Maletic et al., 2007).  
Serotonin is the most extensively studied neurotransmitter in depression, with evidence 
of its deficiency emerging from studies using tryptophan depletion (which reduces 
central serotonin synthesis) (Toker et al., 2010), studies demonstrating abnormalities in 
serotonin receptors in depressed patients (Carr and Lucki, 2011), research showing 
increased availability of monoamine oxidase, an enzyme that metabolises serotonin and 
other monoamines in the brain of depressed people (Meyer et al., 2006), and evidence 
of abnormalities in the expression of the enzyme tryptophan hydroxylase, which is 
involved in serotonin synthesis (Matthes et al., 2010). The monoaminergic theory has 
prompted research into the potential of curcumin in altering neurotransmitters such as 
serotonin, dopamine and noradrenaline. A selection of these studies is reviewed. 
Effects of curcumin on serotonin, dopamine and noradrenaline 
Both animal and in vitro studies conducted over the past decade have now confirmed 
that curcumin is able to influence levels of serotonin, dopamine and noradrenaline in the Antidepressant Potential Modes of Action of Curcumin   
central nervous system.  For example, in a chronic unpredictable mild stress (CUMS) 
model with rats, curcumin reduced serum corticosterone levels and attenuated CUMS-
induced reductions of serotonin (Li et al., 2009).  Curcumin administered to mice for 21 
days prior to the FST was also shown to markedly attenuate FST-induced decreases in 
concentration of serotonin, the serotonin metabolite 5-hydroxyindoleacetic acid, 
noradrenaline and dopamine, as well as increases in serotonin turnover (Xia et al., 
2007).  Similar results were found following the acute administration of curcumin to 
mice one hour prior to the FST. Curcumin dose-dependently increased serotonin, and at 
higher doses increased dopamine levels.  However, no changes in noradrenaline levels 
were found. The researchers demonstrated that curcumin was able to inhibit the 
monoamine oxidase enzymes (both MAO-A, and at higher doses MAO-B) and when 
co-administered with piperine, a bioavailability enhancing agent, the effects of 
curcumin on pharmacological, biochemical, and neurochemical activities were 
potentiated (Kulkarni et al., 2008). Similar findings were obtained when rats were 
subjected to chronic unpredictable stress. Curcumin treatment for 21 days significantly 
reversed the chronic unpredictable stress-induced behavioural (increase in immobility 
period), biochemical (increase in monoamine oxidase activity) and neurochemical 
(depletion of brain monoamine levels, except noradrenaline) alterations. The 
combination of piperine with curcumin again showed significant potentiation of its anti-Antidepressant Potential Modes of Action of Curcumin   
immobility, neurotransmitter enhancing (serotonin and dopamine) and MAO-A effects 
compared to curcumin administration alone (Bhutani et al., 2009). 
In an animal study on the effects of curcumin on serotonin (5-HT) receptors, the 
antidepressant-like effects of curcumin in the FST were related to the serotonergic 
system, possibly due to an interaction with 5-HT1A/1B and 5-HT2C receptors (Wang et 
al., 2008). Further evidence of the monoamine effects of curcumin has been 
demonstrated in rats submitted to a bilateral olfactory bulbectomy. The administration 
of curcumin completely reversed induced reductions in serotonin and noradrenaline in 
the hippocampus and frontal cortex (Xu et al., 2005a). Curcumin also reversed 
reseperine-induced reductions in dopamine, noradrenaline and serotonin in rats (Arora 
et al., 2011). Pre-treatment with curcumin reversed haloperidol-induced reductions of 
dopamine, noradrenaline and serotonin in rats (Bishnoi et al., 2008). In a follow-up 
study, the co-administration of piperine significantly enhanced the effect of curcumin on 
these monoamines (Bishnoi et al., 2011).  
Collectively, these animal studies provide strong support for the monoaminergic effects 
of curcumin. Curcumin enhances levels of serotonin and dopamine and, to a lesser 
extent, noradrenaline, following exposure to acute and chronic stress. The studies 
reviewed in this section indicate that curcumin has an inhibitory effect on monoamine Antidepressant Potential Modes of Action of Curcumin   
oxidase and influences 5-HT1A/1B and 5-HT2C receptors, all of which play a role in 
depression. 
Effects of curcumin on glutamate 
Glutamate is the major excitatory synaptic neurotransmitter in the central nervous 
system and plays a vital role in the regulation of synaptic plasticity, learning, and 
memory (McEntee and Crook, 1993).  Increasing research has demonstrated altered 
levels of glutamate in plasma, cerebrospinal fluid (CSF) and various areas of the brain 
in people with depression. An increasing number of reports also suggest potential 
antidepressant effects of anti-glutamatergic agents, such as ketamine, amantadine, and 
riluzole (Gao and Bao, 2011; McNally et al., 2008).  
Curcumin inhibited the release of glutamate evoked by exposing synaptosomes to the 
K
+ channel blocker 4-aminopyridine (4-AP) (Lin et al., 2011).  Because the inhibitory 
effect of curcumin on glutamate release was completely abolished by the antidepressant 
ﬂuoxetine, it was concluded that these two substances may use a common intracellular 
mechanism to inhibit glutamate release from rat prefrontal cortex nerve terminals. When 
the effects of curcumin and fluoxetine were compared, curcumin had significantly 
greater inhibitory effects on glutamate release than fluoxetine (Lin et al., 2011).  Antidepressant Potential Modes of Action of Curcumin   
Depression and HPA disturbances 
The hypothalamic, pituitary and adrenal (HPA) axis plays a significant role in the 
body’s stress response and is initiated by the secretion of corticotrophin releasing 
hormone (CRH) and arginine-vasopressin (AVP) from the hypothalamus. This, in turn, 
activates the secretion of adrenocorticotropic hormone (ACTH) from the pituitary 
gland, which then stimulates the secretion of glucocorticoids (cortisol in humans and 
corticosterone in rodents) from the adrenal cortex. These glucocorticoids impact on their 
receptors and are involved in the negative feedback control of CRH and AVP release 
from the hypothalamus (Zunszain et al., 2011). 
Abnormalities in the activity of the HPA axis have long been observed in major 
depression (Pariante and Lightman, 2008). This has been characterised by heightened 
cortisol secretion in patients presenting with melancholic depression, and reduced levels 
in people presenting with atypical depression (Gold and Chrousos, 2002). Increasing 
research has also demonstrated that depression is associated with a hypersecretion of 
CRH and impairment in the responsiveness to glucocorticoids, a phenomenon known as 
glucocorticoid resistance (Pariante and Lightman, 2008). Depression is also associated 
with an increased size  and activity of the pituitary and adrenal glands (Nemeroff et al., 
1992). Antidepressant Potential Modes of Action of Curcumin   
Effects of curcumin on HPA disturbances 
A few studies have examined the effect of curcumin in regulating HPA disturbances, 
namely its effect in moderating the hypersecretion of corticosterone and subsequent 
neuroprotection. For example, rats subjected to 3 weeks of corticosterone injections 
exhibited depressive-like behaviours, as demonstrated by a significant decrease in 
sucrose consumption and an increase in immobility time in the FST. These behaviours 
were significantly reduced in those rats treated concurrently with curcumin (Huang et 
al., 2011). In a study on rats exposed to 4 weeks of chronic unpredictable mild stress, 
curcumin was able to moderate increases in serum corticosterone at levels similar to 
those obtained by fluoxetine (Li et al., 2009). In a final study, exposure of 
corticosterone to rat neurons decreased mRNA levels for three serotonin receptor 
subtypes, 5-HT1A, 5-HT2A and 5-HT4. Pre-treatment with curcumin one hour prior to 
corticosterone exposure reversed this effect on 5-HT1A and 5-HT4 receptors, but not for 
the 5-HT2A receptor. Moreover, curcumin significantly reduced neuronal loss, indicating 
that it could protect cells from corticosterone-induced toxicity. Curcumin also inhibited 
corticosterone-induced morphological changes such as increases in soma size, dendritic 
branching and dendritic spine density, and elevated synaptophysin expression in cortical 
neurons.  The antidepressant fluoxetine also provided a protective effect against the 
toxicity of corticosterone and reversed corticosterone-induced down-regulation of 
mRNA levels for three receptors: 5-HT1A, 5-HT2A and 5-HT4 (Xu et al., 2011). Antidepressant Potential Modes of Action of Curcumin   
In sum, these studies highlight the potential protective effects of curcumin on stress-
induced cortisol production. HPA imbalances in depression may prove to be at least 
partly ameliorated by curcumin, although further studies are required. 
Depression and neuroprogression 
Neurogenesis is the process by which new neurons are formed from populations of 
neural stem or progenitor cells residing in discrete regions of the CNS (Abdipranoto et 
al., 2008). Recent research into neuroanatomy and neurochemistry has increasingly 
demonstrated that major depression is associated with impaired neurogenesis, neuronal 
plasticity, and subsequent neurodegeneration. This is indicated by stress-induced 
alterations to the number and shape of neurons and glia in the brain regions of depressed 
patients (Duman, 2009). Depression is also associated with a decrease in proliferation of 
neural stem cells (Eyre and Baune, 2012).  
Neuronal plasticity is influenced by a range of neurotrophic factors, such as brain-
derived neurotrophic factor (BDNF), which is the most abundant and widely distributed 
neurotrophin in the central nervous system (Martinowich and Lu, 2008). BDNF plays a 
role in regulating a large array of functions including neuronal survival, growth and 
proliferation, and levels usually are low in people suffering from major depression 
(Duman, 2009; Lee and Kim, 2010). Chronic administration of several classes of 
antidepressants, including monoamine oxidase inhibitors, SSRIs, tricyclic agents, and Antidepressant Potential Modes of Action of Curcumin   
SNRIs increases BDNF levels (Duman and Monteggia, 2006; Sen et al., 2008).  The 
detrimental effects of early life and chronic stress on BDNF, and evidence of increased 
levels of BDNF following physical exercise and electroconvulsive therapy, provides 
further support for a role of BDNF in the pathogenesis of depression (Martinowich et 
al., 2007; Nagahara and Tuszynski, 2011). 
Neuroprotective effects of curcumin 
Preliminary investigations into the neuroprotective effective of curcumin have provided 
evidence of its ability to enhance BDNF and attenuate stress-induced 
neurodegeneration. Repeated corticosterone injections were shown to significantly 
decrease BDNF levels in the hippocampus and frontal cortex of rats, which curcumin 
was able to significantly ameliorate (Huang et al., 2011). In another study, rats exposed 
to a range of daily stressors over a 20-day period were administered either 3 doses of 
curcumin orally or the antidepressant imipramine. Curcumin administration at higher 
doses reversed the stress-induced decrease in hippocampal neurogenesis in stressed rats 
at levels similar to imipramine treatment. Curcumin also reversed the stress-induced 
decrease in BDNF and 5-HT1A mRNA levels across all hippocampal subfields. These 
effects were similar to those obtained from imipramine (Xu et al., 2007). Further 
evidence for the neuroprotective effects of curcumin was demonstrated in a recent study 
where pre-treatment with curcumin reversed the effect of corticosterone-induced Antidepressant Potential Modes of Action of Curcumin   
neuronal changes in rats (Xu et al., 2011). Curcumin also attenuated quinolinate-
induced excitotoxicity on primary cultures of human neurons (Braidy et al., 2011). 
Depression and mitochondrial disturbances 
Mitochondria are intracellular organelles found in most eukaryotic cells which generate 
most of the cell's supply of adenosine triphosphate (ATP). They are also involved in a 
range of other processes, such as signalling, cellular differentiation, cell death, as well 
as the control of the cell cycle and cell growth (McBride et al., 2006). Because of the 
brain’s significant energy demands, high concentrations of mitochondria are found in 
this region making the brain susceptible to reductions in aerobic metabolism (Pieczenik 
and Neustadt, 2007). 
Malfunction in the biochemical cascade and damage to the mitochondrial electron 
transport chain can lead to mitochondrial dysfunction or disease which has been 
implicated in a range of neuropsychiatric disorders such as depression, bipolar disorder 
and schizophrenia (Gardner and Boles, 2011; Rezin et al., 2009). In depression, 
mitochondrial disturbances such as deletions of mitochondrial DNA (Gardner and 
Boles, 2008a; Shao et al., 2008) and lower activities of respiratory chain enzymes and 
ATP production (Gardner et al., 2003) have been found. Gardner and Boles (2008a; b) 
also showed that in depressed individuals with somatic complaints, the majority had 
lowered ATP production rates in biopsied muscles. Further support for mitochondrial 
dysfunction in depression is demonstrated by increased rates of depression in patients 
with mitochondrial disorders. For example, the lifetime diagnosis of depression in 
patients with mitochondrial disorders was 54% (Fattal et al., 2007). Greater rates of 
depression were also detected in adolescents with mitochondrial disorders (Koene et al., 
2009). Antidepressant Potential Modes of Action of Curcumin   
It has been argued that because depression is associated with increased oxidative and 
nitrosative stress, increased inflammatory pathways, and lowered antioxidant defences, 
this may be a major cause of mitochondrial dysfunction in major depression (Gardner 
and Boles, 2011; Maes et al., 2012c). Kynurenine pathway metabolites such kynurenic 
acid, 3-hydroxykynurenine and 3-hydroxyanthranilic acid, which are dysregulated in 
major depression, can also impair mitochondrial ATP production (Baran et al., 2003).  
Effects of curcumin on mitochondrial function 
Altering the pathogenic cascade associated with mitochondrial dysfunction in major 
depression may be a potential avenue to enhance treatment outcomes in depression. 
Curcumin, with its numerous molecular effects, may be a useful option with a number 
of studies demonstrating protective effects on mitochondria. Curcumin was able to 
attenuate oxidative damage in rat cortical neurons by reducing intracellular production 
of reactive oxygen species (ROS) and protecting mitochondria from oxidative damage 
(Zhu et al., 2004). Treatment with curcumin also lowered aluminium-induced oxidative 
stress and mitochondrial dysfunction in the rat brain, likely by several mechanisms such 
as activation of Heme oxygenase-1, maintenance of glutathione metabolism or by 
scavenging ROS (Sood et al., 2011). Curcumin and its analogues were also able to 
inhibit ROS-induced lipid peroxidation and protein damage in mitochondria (Wei et al., 
2006). Nuclear factor erythroid 2-related factor 2 (Nrf2), which mediates 
neuroprotection against mitochondrial complex I and II inhibitors, is also activated by 
curcumin (Greco and Fiskum, 2010; Jiang et al., 2011) 
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Depression and nitric oxide 
 
Nitric oxide (NO) is an intercellular messenger in the brain, synthesised from the amino 
acid L-arginine by the enzymatic action of nitric oxide synthase (NOS). Three NOS 
isoforms are known to exist in mammals — neuronal NOS (nNOS), inducible NOS 
(iNOS), and endothelial NOS (eNOS) (Alderton et al., 2001). NO plays an important 
role in various physiological and pathological processes, and there has been increasing 
interest in its role in depression and other mental health conditions (Dhir and Kulkarni, 
2011; McLeod et al., 2001; Pinto et al., 2008). According to Dhir & Kulkarni (2011), 
support for a role of NO in the pathogenesis of major depression is provided by studies 
showing that levels of plasma NO and its metabolites are elevated in suicidal and 
depressed patients (Lee et al., 2006; Suzuki et al., 2001), evidence that decreasing or 
blocking the synthesis of NO can induce antidepressant-like effects (Joca and 
Guimaraes, 2006), research demonstrating that NO modulates the production of 
neurotransmitters such as noradrenaline, serotonin, and dopamine (Dhir and Kulkarni, 
2011), and evidence of  lower levels of nNOS in the locus coeruleus of people suffering 
from major depression than in normal controls (Karolewicz et al., 2004). Further 
indirect evidence for NO involvement in major depression is derived from the 
characterisation of circulating antibodies against NO-epitopes. Highly reactive 
substances such as NO-tyrosine, NO-tryptophan and NO-arginine are formed by 
nitration reactions, and increased IgM antibody levels against these NO-adducts have 
been found in depressed patients (Maes et al., 2008b; Maes et al., 2011d). These results 
suggest that increased NO and/or activation of nitration reactions and consequent 
increases in nitrated containing proteins may be involved in the pathophysiology of 
depression (Maes et al., 2011a).  Antidepressant Potential Modes of Action of Curcumin   
Effects of curcumin on nitric oxide 
Several studies have now confirmed that curcumin can regulate levels of nitric oxide. 
Immobilisation-induced restraint stress lasting six hours significantly increased plasma 
nitrite levels in mice, which was attenuated by intraperitoneal delivery of curcumin. 
This effect was enhanced when curcumin was jointly delivered with aminoguanidine, an 
iNOS inhibitor, thereby suggesting curcumin’s possible inhibitory effect on iNOS 
(Gilhotra and Dhingra, 2010). In cultured human neurons, quinolinic acid induced 
nNOS activity and consequently increased nitrite levels. Curcumin dose-dependently 
decreased nNOS activity in human neurons (Braidy et al., 2010). Further evidence of 
curcumin’s nitric oxide inhibitory effect was demonstrated in a study on rats subjected 
to 72 hours of sleep deprivation. This led to increases in nitrite levels, along with 
several markers of oxidative damage. Intraperitoneal treatment with curcumin for 5 days 
had anxiolytic effects and restored nitrite levels. This effect was, however, abolished by 
pre-treatment with L-arginine, a precursor to nitric oxide, but only with the lower dose 
of curcumin of 10mg/kg. The researchers concluded that nitric oxide modulation is 
involved in the protective effect of curcumin in ameliorating sleep deprivation-induced 
behavioural alterations and oxidative damage (Kumar and Singh, 2008).  Antidepressant Potential Modes of Action of Curcumin   
Depression and oxidative stress 
In a review paper, Maes et al. (2011a) confirmed that major depression was 
accompanied by a decreased antioxidant status and by the induction of oxidative and 
nitrosative pathways. This was supported by studies showing significantly reduced 
plasma concentrations of important antioxidants such as vitamin C (Khanzode et al., 
2003), vitamin E (Maes et al., 2000; Owen et al., 2005), and coenzyme Q10 (Maes et al., 
2009b) in depressed patients.  Depression was also accompanied by a lowered total 
antioxidant status (Cumurcu et al., 2009; Sarandol et al., 2007) and reduced antioxidant 
enzyme activity such as glutathione peroxidase (Maes et al., 2011e). Such deficiencies 
can impair protection against reactive oxygen species (ROS), causing damage to fatty 
acids, proteins and DNA (Maes et al., 2011a). In fact, increased levels of 
malondialdehyde, a measure of lipid peroxidation,  were found in depressed patients 
(Ozcan et al., 2004; Sarandol et al., 2007; Wei et al., 2009), as have increased levels of 
8-hydroxy-2-deoxyguanosine (8-OH-dG), a measure of oxidative damage to DNA 
(Forlenza and Miller, 2006; Maes et al., 2009a). 
Further support for an association between oxidative stress and depression is provided 
by a few studies that demonstrate antioxidant properties of antidepressant medications. 
However, not all studies have uniformly identified reductions in oxidative markers 
following antidepressant medications, necessitating further research in this area (Ng et Antidepressant Potential Modes of Action of Curcumin   
al., 2008). Clinical studies into the efficacy of antioxidant therapies to alleviate 
depressive symptoms are lacking although N-acetylcysteine (NAC), a powerful 
antioxidant, was found to be useful for depressive episodes in bipolar disorder 
(Magalhaes et al., 2011). Zinc, which serves as a strong antioxidant, also has evidence 
of antidepressant activity (Szewczyk et al., 2011). 
Antioxidant effects of curcumin 
Investigations into the pharmacodynamics of curcumin have consistently demonstrated 
it to be a potent antioxidant (Ak and Gulcin, 2008; Menon and Sudheer, 2007), at least 
ten times more active as an antioxidant than vitamin E (Ak and Gulcin, 2008). In 
relation to a selection of the oxidative markers associated with depression, curcumin is 
able to lower levels of malondialdehyde (Rai et al., 2010), 8-OH-dG (Naik et al., 2011; 
Rai et al., 2010; Shih and Lin, 1993), and increase the activity of the antioxidant 
enzymes superoxide dismutase and glutathione peroxidase (Manikandan et al., 2011; 
Naik et al., 2011). Curcumin also attenuated increased markers of oxidative stress in 
rats undergoing chronic stress (Bhatia et al., 2011). In recent studies, curcumin also up-
regulated Nrf2, a transcription factor that induces the expression of various genes 
including those that encode for several antioxidant enzymes (Scapagnini et al., 2011; 
Yang et al., 2009). Antidepressant Potential Modes of Action of Curcumin   
Depression and intestinal hyperpermeability 
The intestinal epithelium is the largest mucosal surface in the human body and provides 
an interface between the external environment and the host (Fasano and Shea-Donohue, 
2005). Normally, the intestinal epithelium provides a semi-permeable wall which allows 
nutrients to be absorbed while preventing larger, potentially toxic, antigenic, or 
pathogenic molecules or organisms from passing into the bloodstream. However, the 
permeability of the intestinal epithelium can become compromised leading to a 
condition known as intestinal hyperpermeability or ‘leaky gut.’ This results in an 
increased diffusion of antigenic food molecules and translocation of bacteria from the 
gut into extra-intestinal sites which can then trigger an immune response (Miller, 1997).  
Lipopolysaccharides (LPS) are large molecules found in the outer membrane of Gram-
negative bacteria and, during a state of intestinal hyperpermeability, are known to 
translocate into the systemic circulation in greater quantities (Maes et al., 2008a). Once 
the LPS are translocated into the blood, an inflammatory process is generated and is 
associated with increased neuroinﬂammation and secretion of proinﬂammatory 
cytokines, such as IL-1β, IL-6 and TNF-α (Dunn, 2006; Henry et al., 2008; Huang et al., 
2008; Qin et al., 2007). LPS are also able to activate IDO production leading to 
increased kynurenine metabolites and tryptophan breakdown (Dobos et al., 2012; Fu et 
al., 2010; O'Connor et al., 2009). Antidepressant Potential Modes of Action of Curcumin   
Research into the relationship between LPS, intestinal permeability and depression has 
demonstrated that LPS have the capacity to induce depressive behaviour in animals 
(Henry et al., 2008; Yirmiya, 1996). Interestingly, antidepressants such as fluoxetine 
and imipramine attenuate behavioural responses to immune challenges, such as LPS 
(Yirmiya et al., 2001). In a recent study, the reverse was demonstrated where LPS 
reduced the antidepressant effects of fluoxetine in a chronic, unpredictable mild stress 
model in mice (Wang et al., 2011). 
Investigations into the incidence of intestinal hyperpermeability in patients with major 
depressive disorder have confirmed an increased translocation of LPS from Gram- 
negative enterobacteria in depressed patients. This was demonstrated by increased 
serum IgM and IgA levels directed against LPS of Gram-negative enterobacteria (Maes 
et al., 2012b; Maes et al., 2008b).   Maes and colleagues concluded that depressive 
disorder was accompanied by increased gut permeability which was associated with an 
immune response directed against LPS produced by enterobacteria.  
Effects of curcumin on the LPS-induced immune response 
Several studies have investigated the protective effects of curcumin on LPS 
administration. In two separate studies, curcumin decreased NO production in LPS-
stimulated microglial cells in a dose-dependent manner (Jung et al., 2006; Tocharus et 
al., 2012). Both pre- and post-treatment with curcumin diminished LPS-induced Antidepressant Potential Modes of Action of Curcumin   
dopamine neurotoxicity in a dose-dependent manner. LPS-induced production of many 
proinflammatory factors and their gene expressions such as TNF-α, NO, PGE2 and IL-
1β was also dramatically reduced following curcumin treatment. Curcumin also 
decreased LPS-induced activation of two transcription factors - nuclear factor kappaB 
and activator protein-1 (Huang et al., 2008). The benefits of curcumin may also occur 
through its ability to reduce the translocation of bacteria into extraintestinal sites, such 
as mesenteric lymph nodes, liver, spleen, and/or bloodstream (Karatepe et al., 
2010)Given the potential of LPS to induce depressive-like behaviour in animals, and an 
increased translocation of LPS in depressed patients resulting from increased intestinal 
hyperpermeability, the ameliorating effects on LPS-induced inflammation provides 
another potential antidepressant mode of action of curcumin. 
Conclusion 
<<<insert Figure 4 near here> 
While clinical trials on the antidepressant effects of curcumin are required to determine 
the efficacy of this natural substance, this paper highlights the multiple potential 
antidepressant modes of action of curcumin. As discussed above and summarised in 
Figure 4, curcumin has been shown through in vitro and in vivo studies to influence a 
range of neurotransmitters and hormones commonly observed to be disturbed in major 
depression. It also has the potential to provide neuroprotective effects, and shows some Antidepressant Potential Modes of Action of Curcumin   
promise as a protective agent from stress-induced neurotoxicity. Curcumin’s anti-
inflammatory and antioxidant effects are already well-recognised and may prove to be 
another potential mode of action in treating depression. 
Unfortunately, a commonly cited problem associated with curcumin relates to its poor 
bioavailability via oral ingestion, limiting its potential clinical application (Anand et al., 
2007). However, recent efforts to enhance its bioavailability have shown significant 
promise. For example, blood levels of the patented formulation BCM-95
®CG was found 
to be 6.93 times higher than standard curcumin, and 6.3-fold higher than a curcumin-
lecithin-piperine formula (Antony et al., 2008). In another human study on the patented 
curcumin formula, Meriva
®, its total curcuminoid absorption was shown to be 29-fold 
higher than an unformulated curcuminoid mixture (Cuomo et al., 2011). Curcumin 
administered with the agent piperine also increases oral bioavailability (Shoba et al., 
1998). While no research has yet assessed whether this increased absorption is 
associated with increased clinical efficacy, it is hoped that these methods of delivery 
may at least partly overcome problems associated with curcumin’s poor oral absorption 
and therefore enhance its utility in clinical settings. 
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